

performance test (DS-CPT) and contextual processing with a visual delayed non-matched to sample task (DNMS).

**Results:** Citalopram treatment did not produce measurable changes to reaction time, hit rate and false alarms in the DS-CPT at any time point. The citalopram treated group underperformed in the DNMTS after acute treatment and this decrement appeared to persist at 28 days.

**Conclusions:** Our results suggest that SSRI treatment may lead to small but measurable decrements in contextual processing, which require further confirmation, and evaluation in clinical populations.

## P0027

Case of Successful treatment of voyeurism

E. Becirovic, A. Arnautalic, R. Softic, E. Avdibegovic. *Klinika Za Psihijatriju, Tuzla, Bosnia and Herzegovina*

Patient 27 years old received at clinic in upset state, potentially destructive and suicidal. After thorough anamnesis, in absence of his wife, he presents with symptoms of voyeurism in comorbidity with fetishism. Disorder starts unexpectedly several years ago. His neighborhood knows nothing of that. We started treatment with antidepressants and antipsychotic on which he reacted well. Several days later he presents completely free of symptoms. He becomes able to admit his wife of his disorder and readies to work it out together. Few days later he is dismissed from the treatment.

## P0028

Are life events prior to first episode of major depression a predictor of medical treatment outcome?

C. Bock<sup>1</sup>, J.D. Bukh<sup>1</sup>, M.V. Christensen<sup>1</sup>, U. Gether<sup>2</sup>, L.V. Kessing<sup>1</sup>. <sup>1</sup>*Department of Psychiatry, Rigshospitalet, and Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark* <sup>2</sup>*Center of Pharmacogenomics, University of Copenhagen, Copenhagen, Denmark*

**Background and Aims:** The association between stressful life events and onset of major depression has been verified in various studies, but more dubious are results concerning the association between life events and treatment outcome.

This study is part of a multicenter investigation evaluating genetic and psychosocial factors influence on outcome after pharmacological treatment of depression.

**Methods:** All cases of admittance or outpatient contact to a psychiatric department in Denmark are covered by the Danish Psychiatric Central Research Register. In this study we obtain personal data on all patients in a defined region of Denmark (Zealand) recently discharged with an ICD-10 diagnosis of a single depressive episode. These patients are invited to an interview including structural interviews and questionnaires to evaluate the presence of previous or recent life events (IRLE), personality traits (EPQ) or disorders (SCID), a family history of affective disorder, and the outcome of pharmacological treatment of their depression (TRAQ). The clinical diagnosis of depression is confirmed by the SCAN semistructural interview. The study is scheduled to include approximately 400 patients.

**Results:** Data collection continues until January 2008 and statistical evaluation will be completed subsequently. Results are ready for presentation in April 2008.

**Conclusions:** Compared with a prospective randomized study the drawback of the present study may be less validity of response to

antidepressive treatment, on the other hand the present design enables an investigation of a large and representative sample of patients to reveal the influence of life events on the outcome of pharmacological treatment of depression.

## P0029

Genetic Polymorphisms and the outcome of antidepressant Treatment

J.D. Bukh<sup>1</sup>, C. Bock<sup>1</sup>, M.V. Christensen<sup>1</sup>, U. Gether<sup>2</sup>, L.V. Kessing<sup>1</sup>. <sup>1</sup>*Psychiatric Centre, University Hospital of Copenhagen, Copenhagen, Denmark* <sup>2</sup>*Center for Pharmacogenomics, University of Copenhagen, Copenhagen, Denmark*

**Background and Aims:** The genetic contribution to individual differences in drug response is probably polygenetic with a number of susceptibility genes and gene interactions. The non-genetic factors are likewise comprehensive, interacting and might even be under genetic influence themselves. Thus, antidepressant response is a complex and multifactorial phenomenon.

This study sought to examine the effects of various genetic variations on the outcome of antidepressant treatment taking into account the possible interactions with environment and personality.

**Methods:** Patients discharged from a psychiatric clinic in a region of Denmark with the diagnosis of single depressive episode are identified via the Danish Psychiatric Central Research Register and invited to participate in interviews regarding present psychiatric illness, treatment response, recent life events, and personality disorder. Further, blood test for genetic analyses are taken and the participants complete questionnaires regarding present symptoms, personality traits, coping, and side effects.

The study will include approximately 400 patients.

**Results:** Data collection will proceed until January 2008, and the presentation will therefore include new and unpublished results.

Associations between genetic polymorphisms (including the genes encoding the serotonin transporter, catechol-O-methyl-transferase, 5-HT<sub>2</sub> receptors, dopamin beta-hydroxylase, cytochrome P450 and brain derived growth factor) and outcome of antidepressant treatment will be presented.

**Conclusion:** The systematic recruitment of a relatively large, unselected and ethnic as well as phenotypic homogeneous sample of patients and the inclusion of genetic as well as non-genetic predictors of treatment response will make it possible throw new light on the role of genetic variation in the treatment of depression.

## P0030

Treatment of melancholy with Duloxetine

A. Chinchilla, M.F. Pando, I. Gobernado, M. Martin, J. Perez-Templado, M.C. Morcillo, R. Arroyo, M.D. Crespo, M. Vega. *Psychiatry Department, Ramon Y Cajal Hospital, Madrid, Spain*

We have administered a dosage of 120 mg a day of duloxetine to 11 patients diagnosed with melancholy. On these patients, we studied sociodemographical and clinical variables, previous episodes and records, former response to treatment and adherence. They were evaluated at the beginning and then 15, 30, 60, 90 and 120 days after commencing the treatment. The therapeutic response was measured using the Hamilton scale for depression (HDRS). Other items observed were the side-effects and adherence. As an additional

medication we used benzodiazepines (anxiolytics and hypnotics). The group's average at the HDRS was 46 points.

After 30 days there was an improvement on 9 patients (82%), with a HDRS average score of 30 points. After 90 days there was an improvement on 10 patients (91%), and the HRDS average score was 14. After 120 days the HRDS average score of those 10 patients was 8 points.

One of the patients had no response and the treatment had to be reinforced. Only two of them had side-effects, like nausea, constipation, tremulousness and restlessness. We believe that duloxetine is one of the first choices as a treatment for melancholy.

### P0031

Pooled analysis of the safety and tolerability of desvenlafaxine Succinate compared with placebo in the treatment of major depressive disorder

A.H. Clayton<sup>1</sup>, S.G. Kornstein<sup>2</sup>, L. Lamm<sup>3</sup>, G. Rosas<sup>3</sup>, K.A. Tourian<sup>3</sup>. <sup>1</sup> *University of Virginia, Charlottesville, VA, USA* <sup>2</sup> *Virginia Commonwealth University, Richmond, VA, USA* <sup>3</sup> *Wyeth Research, Collegeville, PA, USA*

**Objective:** To characterize the safety and tolerability of desvenlafaxine succinate (DVS) in patients with major depressive disorder (MDD).

**Methods:** Pooled data from 7 double-blind, placebo-controlled studies were analyzed. Adult outpatients with DSM-IV MDD received DVS or placebo for 8 weeks. Four studies employed flexible dosing of DVS (100-200mg/d [1 study]; 200-400mg/d [3 studies]); 3 studies evaluated fixed doses (100/200/400mg/d [1 study]; 200/400mg/d [2 studies]). Vital signs and treatment-emergent adverse events (TEAEs) were evaluated. In the fixed-dose subset of studies, dose-related effects were analyzed.

**Results:** The overall safety population consisted of 2014 patients (DVS: n=1211; placebo: n=803); 60% were women. Adverse events were responsible for discontinuations in 4% of placebo-treated patients and 15% of DVS-treated patients. Discontinuation rates increased with dose (10% with 100mg/d to 17% with 400mg/d) in the subset of fixed-dose studies. TEAEs were consistent with the serotonin-norepinephrine reuptake inhibitor (SNRI) class. Nausea was generally mild to moderate with a median duration less than or = to 6 days; the incidence decreased to placebo-like rates after week 1. With all doses of DVS, small but statistically significant changes in mean blood pressure were observed. Mean changes in pulse rate and the proportion of potentially clinically important increases in sustained elevations in supine diastolic blood pressure were higher for patients receiving 200/400mg/d than among placebo-treated subjects; values for these parameters with the 100mg/d dose did not differ from placebo.

**Conclusions:** DVS treatment exhibited a safety and tolerability profile that was generally consistent with the SNRI class.

### P0032

Effects of Escitalopram on the processing of emotional faces

W.C. Alves-Neto, V.G. Guappo, F.G. Graeff, C.M. Del-Ben. *Division of Psychiatry, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil*

**Background and Aims:** The aim of this study was to verify the effects of the selective serotonin reuptake inhibitor escitalopram on the recognition of facial emotional expressions.

**Method:** Twelve healthy males completed two experimental sessions each, separated by at least 2 weeks, in a randomized, balanced order, double-blind design. An oral dose of escitalopram (10 mg) or placebo was given 3 hours before the task. Face recognition task: Subjects were presented with pictures of faces from the Pictures of Facial Affect Series (Ekman and Friesen, 1976). Faces with six basic emotions (anger, disgust, fear, happiness, sadness and surprise) had been morphed between neutral (0%) and each standard emotion (100%), in 10% steps. Accuracy was analyzed through MANOVA with repeated measures. Values of  $p < 0.05$  were considered significant.

**Results:** Volunteers recognized more accurately negative emotions in female faces than in male faces, whereas happiness was identified more easily in male faces. In general, the acute administration of a single dose of escitalopram increased the accuracy of the recognition of angry and sad faces. When the gender of the faces was analyzed, escitalopram facilitated the recognition of sad expressions and impaired the recognition of happy faces in male, but not in female faces. A global order effect has also been found; the administration of escitalopram in the second experimental session facilitated the recognition of emotional expressions.

**Conclusions:** These results indicate that serotonin modulates the recognition of emotional faces. Previous experience and gender of the emotional face interact with this modulation.

### P0033

The impact of treatment on quality of life in major depressive disorder (MDD) and generalized anxiety disorder (GAD)

K. Demyttenaere. *Department of Psychiatry, University Hospital Gasthuisberg, Leuven, Belgium*

**Objective:** To compare the quality of life using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) in patients with MDD or GAD, before and after treatment and to compare remission based on symptoms versus functioning.

**Methods:** Q-LES-Q and symptom-specific MADRS and HAMA data from 8 published randomised, 8-week, double-blind, placebo-controlled clinical trials with escitalopram were used. The short form of the patient-rated Q-LES-Q was used to assess patients' perceived quality of life and satisfaction at baseline and at last assessment. ANCOVA was used, adjusting for study, centre, baseline value, and treatment. MADRS and HAMA total scores were equated to Q-LES-Q using the method of equipercentile linking.

**Results:** MDD or GAD patients report a substantial degree of impairment in their quality of life (64% and 76% of community norm, respectively). Treatment with escitalopram resulted in statistically and clinically significant improvement in patient quality of life. The improvement was greater in remitters (MADRS $\leq$ 12 or HAMA $\leq$ 7) than in non-remitters and greater in patients treated with escitalopram than in patients treated with placebo. There was a strong correlation between each symptom scale (MADRS, HAMA) and the Q-LES-Q. The present analyses suggest that scores as low as 3-8 on the MADRS and 5-10 on the HAMA (complete remission) correspond to a Q-LES-Q score of 58 (+/- 10%), found in community comparison subjects.

**Conclusions:** Treatment with escitalopram results in a statistically significant improvement of quality of life in patients with MDD or GAD.